NEW YORK (GenomeWeb) – Biodesix is aiming to make inroads into the Chinese market with its recent agreement with life sciences firm Bioyong.

The deal, under which Bioyong will pay Biodesix up to $38 million, provides the Boulder, Colorado-based molecular diagnostics firm access to Bioyong's network of hospital-installed MALDI mass specs on which the partners hope to place assays including Biodesix's Veristrat lung cancer test as well as other diagnostics currently under development, said David Brunel, Biodesix's director and CEO.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.